Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus

Kaul, 2016, Systemic lupus erythematosus, Nat. Rev. Dis. Prim., 2, 16039, 10.1038/nrdp.2016.39 Bakshi, 2018, Unmet needs in the pathogenesis and treatment of systemic lupus erythematosus, Clin. Rev. Allergy Immunol., 55, 352, 10.1007/s12016-017-8640-5 Choi, 2012, The pathogenesis of systemic lupus erythematosus – an update, Curr. Opin. Immunol., 24, 651, 10.1016/j.coi.2012.10.004 von Spee-Mayer, 2016, Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus, Ann. Rheum. Dis., 75, 1407, 10.1136/annrheumdis-2015-207776 Klatzmann, 2015, The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases, Nat. Rev. Immunol., 15, 283, 10.1038/nri3823 Rosenberg, 1994, Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2, JAMA, 271, 907, 10.1001/jama.1994.03510360033032 Malek, 2002, CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2, Immunity, 17, 167, 10.1016/S1074-7613(02)00367-9 Yu, 2009, A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells, Immunity, 30, 204, 10.1016/j.immuni.2008.11.014 Zhao, 2018, Fine tuning subsets of CD4+ T cells by low-dosage of IL-2 and a new therapeutic strategy for autoimmune diseases, Int. Immunopharmacol., 56, 269, 10.1016/j.intimp.2018.01.042 He, 2016, Low-dose interleukin-2 treatment selectively modulates CD4 + T cell subsets in patients with systemic lupus erythematosus, Nat. Med., 22, 991, 10.1038/nm.4148 Rosenzwajg, 2019, Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial, Ann. Rheum. Dis., 78, 209, 10.1136/annrheumdis-2018-214229 He, 2020, Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial, Ann. Rheum. Dis., 79, 141, 10.1136/annrheumdis-2019-215396 Humrich, 2019, Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial, Lancet Rheumatol., 1, e44, 10.1016/S2665-9913(19)30018-9 Xu, 2019, New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases, Int. Immunopharmacol., 72, 322, 10.1016/j.intimp.2019.03.064 Dixit, 2021, NKTR-358: a novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases, J. Transl. Autoimmun, 4, 100103, 10.1016/j.jtauto.2021.100103 Li, 2015, FOXP3 + regulatory T cells and their functional regulation, Cell. Mol. Immunol., 12, 558, 10.1038/cmi.2015.10 Wieczorek, 2009, Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue, Cancer Res., 69, 599, 10.1158/0008-5472.CAN-08-2361 Abbas, 2018, Revisiting IL-2: biology and therapeutic prospects, Sci. Immunol., 3, 10.1126/sciimmunol.aat1482 Saadoun, 2011, Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis, N. Engl. J. Med., 365, 2067, 10.1056/NEJMoa1105143 Koreth, 2011, Interleukin-2 and regulatory T cells in graft-versus-host disease, N. Engl. J. Med., 365, 2055, 10.1056/NEJMoa1108188 Koreth, 2016, Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease, Blood, 128, 130, 10.1182/blood-2016-02-702852 Lotze, 1985, In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2, J. Immunol., 135, 2865, 10.4049/jimmunol.135.4.2865 Bayer, 2013, The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation, Immunol. Res., 57, 197, 10.1007/s12026-013-8452-5 Visweswaraiah, 2021, Generation of PT101, a highly selective IL-2 mutein for treatment of autoimmune diseases, Ann. Rheum. Dis., 80, 13, 10.1136/annrheumdis-2021-eular.2097 Van Gool, 2014, Interleukin-5–producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy, Blood, 124, 3572, 10.1182/blood-2014-07-587493 Dutcher, 2014, High dose interleukin-2 (Aldesleukin) – expert consensus on best management practices-2014, J. Immunother. Cancer, 2, 26, 10.1186/s40425-014-0026-0 Sakaguchi, 2010, FOXP3+ regulatory T cells in the human immune system, Nat. Rev. Immunol., 10, 490, 10.1038/nri2785 Thornton, 2019, Helios+ and Helios- Treg subpopulations are phenotypically and functionally distinct and express dissimilar TCR repertoires, Eur. J. Immunol., 49, 398, 10.1002/eji.201847935 Cooper, 2001, Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset, Blood, 97, 3146, 10.1182/blood.V97.10.3146 Ito, 2014, Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers, Mol. Ther., 22, 1388, 10.1038/mt.2014.50 Ruiz-Irastorza, 2020, Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs, Rheumatology, 59, v69, 10.1093/rheumatology/keaa403 Yasuda, 2019, Emerging targets for the treatment of lupus erythematosus: there is no royal road to treating lupus, Mod. Rheumatol., 29, 60, 10.1080/14397595.2018.1493909 Vukelic, 2018, Novel treatments in lupus, Front. Immunol., 9, 2658, 10.3389/fimmu.2018.02658 Liossis, 2021, What's new in the treatment of systemic lupus erythematosus, Front. Med., 8, 655100, 10.3389/fmed.2021.655100 Humrich, 2016, Restoring regulation - IL-2 therapy in systemic lupus erythematosus, Expet Rev. Clin. Immunol., 12, 1153, 10.1080/1744666X.2016.1199957 Rahman, 2008, Systemic lupus erythematosus, N. Engl. J. Med., 358, 929, 10.1056/NEJMra071297 Dörner, 2011, Abnormalities of B cell subsets in patients with systemic lupus erythematosus, J. Immunol. Methods, 363, 187, 10.1016/j.jim.2010.06.009 Xia, 2021, Follicular regulatory T cells in systemic lupus erythematosus, J. Immunol. Res., 2021, 9943743, 10.1155/2021/9943743 Suárez-Fueyo, 2016, T cells in systemic lupus erythematosus, Curr. Opin. Immunol., 43, 32, 10.1016/j.coi.2016.09.001 Jucaud, 2016, Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: clinical relevance of HLA-F autoantibodies, Clin. Exp. Immunol., 183, 326, 10.1111/cei.12724 Mizui, 2018, Targeting regulatory T cells to treat patients with systemic lupus erythematosus, Front. Immunol., 9, 786, 10.3389/fimmu.2018.00786 Boothby, 2020, Regulatory T cells in skin injury: at the crossroads of tolerance and tissue repair, Sci. Immunol., 5, 10.1126/sciimmunol.aaz9631